Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-10-29 Call Transcript
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an official communication from Mankind Pharma Limited dated October 29, 2025, informing stock exchanges and the public about an upcoming investor conference call scheduled for November 6, 2025. The subject explicitly states it is an "Intimation of Investor Conference Call for Q2 & H1 FY26 with Senior Management." The content includes details about the call timing, dial-in numbers, and the management team who will participate. There are no financial statements or detailed financial data presented in the document. It is an announcement of the conference call event rather than the transcript or report of the call itself. Therefore, this document fits the category of a Call Transcript (CT) announcement or invitation. However, since it is only an invitation/intimation and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high due to clear references to the earnings call and no other competing document types.
2025-10-29 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-27 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal notice titled 'Intimation of Board Meeting' addressed to stock exchanges, referencing SEBI Listing Regulations. It announces the scheduled date of a Board of Directors meeting to consider and approve unaudited financial results for a quarter and half year period. It also mentions the closure of the trading window due to insider trading regulations. The document is short (1733 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. Therefore, it is a Board/Management Information filing, as it relates to board meeting scheduling and compliance notifications.
2025-10-27 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official announcement dated October 10, 2025, from Mankind Pharma Limited addressed to stock exchanges (BSE and NSE). It provides an update on the execution of a Business Transfer Agreement (BTA) for the acquisition of a business segment from a wholly owned subsidiary. The document references compliance with SEBI Listing Regulations and previous disclosures. It does not contain financial statements or detailed financial analysis but rather informs about a corporate transaction (acquisition) and its terms. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising or capital structure changes through acquisition. The document length is short and is an announcement, not a full report or detailed presentation.
2025-10-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialisation/rematerialisation of shares for the quarter ended September 30, 2025. It is a compliance certificate from the Registrar and Share Transfer Agent addressed to the stock exchanges and the company secretary. The document is short (2096 characters) and primarily serves as a regulatory compliance attestation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and regulatory announcements that do not fit other specific categories.
2025-10-04 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the announcement of the company's quarterly and half-yearly unaudited financial results. It references regulatory compliance with insider trading regulations and mentions the upcoming declaration of financial results for the quarter and half year ending September 30, 2025. The document does not contain any financial data or results itself, nor does it include a report or detailed financial analysis. Instead, it is an announcement related to trading restrictions in anticipation of a financial report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers compliance-related announcements and notifications that do not fit other specific categories.
2025-09-25 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.